TY - JOUR
T1 - Issues in experimental design and endpoint analysis in the study of experimental cytotoxic agents in vivo in breast cancer and other models
AU - Clarke, Robert
PY - 1997
Y1 - 1997
N2 - Considerable effort has been placed into the identification of new antineoplastic agents to treat breast cancer and other maligant diseases. The basic approaches, in terms of model selection, endpoints, and data analysis, have changed in the previous few decades. This article deals with many of the issues associated with designing in vivo studies to investigate the activity of experimental and established compounds and their potential interactions. Endpoints for both in situ and excision assays are described, including approaches for determining cell kill, tumor growth delay, survival, and other estimates of activity. Suggestions for approaches that may limit the number of animals also are included, as are possible alternatives for death as an experimental endpoint. Other concerns, such routes for drug administration, drug dosage, and preliminary assessments of toxicity also are addressed. Statistical considerations are only briefly discussed, since these are addressed in detail in the accompanying article by Hanfelt. The approaches suggested within this article are presented to draw attention to many of the key issues in experimental design and are not intended to exclude other approaches.
AB - Considerable effort has been placed into the identification of new antineoplastic agents to treat breast cancer and other maligant diseases. The basic approaches, in terms of model selection, endpoints, and data analysis, have changed in the previous few decades. This article deals with many of the issues associated with designing in vivo studies to investigate the activity of experimental and established compounds and their potential interactions. Endpoints for both in situ and excision assays are described, including approaches for determining cell kill, tumor growth delay, survival, and other estimates of activity. Suggestions for approaches that may limit the number of animals also are included, as are possible alternatives for death as an experimental endpoint. Other concerns, such routes for drug administration, drug dosage, and preliminary assessments of toxicity also are addressed. Statistical considerations are only briefly discussed, since these are addressed in detail in the accompanying article by Hanfelt. The approaches suggested within this article are presented to draw attention to many of the key issues in experimental design and are not intended to exclude other approaches.
KW - Breast cancer
KW - Cell lines
KW - Cytotoxic drugs
KW - Resistance
KW - Synergy
KW - Xenografts
UR - http://www.scopus.com/inward/record.url?scp=0031471632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031471632&partnerID=8YFLogxK
U2 - 10.1023/A:1005938428456
DO - 10.1023/A:1005938428456
M3 - Review article
C2 - 9478280
AN - SCOPUS:0031471632
SN - 0167-6806
VL - 46
SP - 255
EP - 278
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
IS - 2-3
ER -